thalidomide has been researched along with Acute Symptom Flare in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options." | 2.53 | Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. ( Aldredge, L; Armstrong, AW; Yamauchi, PS, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pacifico, A | 1 |
| d'Arino, A | 1 |
| Pigatto, PDM | 1 |
| Malagoli, P | 1 |
| Damiani, G | 1 |
| Krishnamoorthy, G | 1 |
| Kotecha, A | 1 |
| Pimentel, J | 1 |
| Armstrong, AW | 1 |
| Aldredge, L | 1 |
| Yamauchi, PS | 1 |
1 review available for thalidomide and Acute Symptom Flare
| Article | Year |
|---|---|
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progr | 2016 |
2 other studies available for thalidomide and Acute Symptom Flare
| Article | Year |
|---|---|
COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
Topics: Administration, Oral; Adult; Aged; COVID-19; COVID-19 Vaccines; Female; Humans; Male; Middle Aged; O | 2021 |
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Humans; Male; Middle Aged; Pruritu | 2019 |